Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification

Area of Science:

• Oncology
• Pathology
• Genetics

Background:

• Primary ovarian angiosarcoma is an extremely rare and aggressive malignancy.
• Angiosarcomas can metastasize, presenting complex diagnostic and therapeutic challenges.

Purpose of the Study:

• To report a rare case of primary ovarian angiosarcoma with possible bone metastases.
• To investigate the pathological and genetic features of the tumor.
• To evaluate the long-term efficacy of a gemcitabine-based chemotherapy regimen.

Main Methods:

• Retrospective analysis of a patient diagnosed with ovarian angiosarcoma.
• Immunohistochemical analyses for pathological diagnosis and tumor feature investigation.
• Fluorescence in situ hybridization (FISH) to detect gene amplification.

Main Results:

• The patient achieved at least 7 years of progression-free survival after gemcitabine-based adjuvant chemotherapy.
• MYC gene amplification and c-Myc protein overexpression were detected in the tumor.
• The patient had a rare ovarian angiosarcoma with possible bone metastases.

Conclusions:

• Gemcitabine-based chemotherapy may be effective for ovarian angiosarcoma, particularly in cases with MYC amplification.
• MYC amplification and c-Myc overexpression could be potential biomarkers for treatment response.
• Long-term survival is achievable even in aggressive ovarian angiosarcoma cases with appropriate treatment.